Paula Tanabe

Paula Tanabe

Auto-generated profile, based on publicly available information

Paula Tanabe

Duke University School of Nursing and Medicine

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2013 in Annals of Emergency Medicine
Verified
Journal Article
Closed access
JGJeffrey A. Glassberg
Jeffrey A. Glassberg
PTPaula Tanabe
Paula Tanabe
ACAnnie Chow
Annie Chow
KHKatrina Harper
Katrina Harper
CHCarlton Haywood
Carlton Haywood
LRLynne D. Richardson
Lynne D. Richardson

19 October 2017 in American Journal of Hematology
Verified
Journal Article
Open access
PDF file
PTPaula Tanabe
Paula Tanabe
SSSusan Silva
Susan Silva
HBHayden B. Bosworth
Hayden B. Bosworth
RCRegina Crawford
Regina Crawford
JPJudith A. Paice
Judith A. Paice
JGJeffrey Glassberg
Jeffrey Glassberg
Limited evidence guides opioid dosing strategies for acute Sickle Cell (SCD) pain. We compared two National Heart, Lung and Blood (NHBLI) recommended opioid dosing strategies (weight‐based vs. patient‐specific) for ED treatment of acute vaso‐occlusive episodes (VOE).A prospective randomized controlled trial (RCT) was conducted in two ED's. Adults ≥ 21 years of age with SCD disease were eligible. Among the 155 eligible patients, 106 consented and 52 had eligible visits. Patients were pre‐enrolled in the outpatient setting and randomized to one of two opioid dosing strategies for a future ED visit. ED providers accessed protocols through the electronic medical record. Change in pain score (0‐100 mm VAS) from arrival to ED disposition, as well as side effects were assessed. 52 patients (median age was 27 years, 42% were female, and 89% black) had one or more ED visits for a VOE (total of 126 ED study visits, up to 5 visits/patient were included). Participants randomized to the patient‐specific protocol experienced a mean reduction in pain score that was 16.6 points greater than patients randomized to the weight‐based group (mean difference 95% CI = 11.3 to 21.9, P = 0.03). Naloxone was not required for either protocol and nausea and/or vomiting was observed less often in the patient‐specific protocol (25.8% vs 59.4%, P = 0.0001). The hospital admission rate for VOE was lower for patients in the patient‐specific protocol (40.3% vs 57.8% P = 0.05). NHLBI guideline‐based analgesia with patient‐specific opioid dosing resulted in greater improvements in the pain experience compared to a weight‐based strategy, without increased side effects.

16 April 2012 in Academic Emergency Medicine
Verified
Journal Article
Open access
PDF file
PTPaula Tanabe
Paula Tanabe
JHJohn W. Hafner
John W. Hafner
ZMZoran Martinovich
Zoran Martinovich
NANicole Artz
Nicole Artz
ACADEMIC EMERGENCY MEDICINE 2012; 19: 430–438 © 2012 by the Society for Academic Emergency Medicine Objectives:  The aims of this study were to 1) estimate differences in pain management process and patient‐reported outcomes, pre‐ and postimplementation of analgesic protocols for adults with sickle cell disease (SCD), and 2) examine the effects of site and visit frequency on changes in pain scores and time to analgesic.Methods:  A multicenter, prospective, longitudinal study enrolled patients from three academic medical centers between October 2007 and September 2009. All ED patients 18 years or older with a chief complaint of a sickle cell pain episode were enrolled. Sites formed a SCD quality improvement (QI) team and implemented standard nurse‐initiated emergency department (ED) analgesic protocols; outcomes were compared between study periods defined as pre‐ and postimplementation of protocols. Medical record review was conducted to measure time to administration of initial analgesic, opioids used, route of opioid administration, the change in pain scores from arrival to discharge (negative numbers reflect a decrease in pain scores), and the number of ED visits per individual patient during the study period at each site. On day 7 after the ED visit, a follow‐up phone interview was conducted. Patients were queried about their ED pain management using a scale from 1 to 10 (1 = outstanding, 10 = worst). Descriptive statistics are used to report the results. Ordinary least‐squares regression models were constructed to measure the effect of time period, site, and number of visits per patient on change in pain score.Results:  During the study period, 342 unique patients (57% female, mean ± SD age =32 ± 11 years) were enrolled and had a total of 2,934 visits. There was no difference in time to administration of the initial analgesic between study periods. Overall, there was a significant decrease in pain scores from arrival to discharge between the pre‐ and postintervention study periods: the average difference in arrival to discharge pain scores (cm) was greater during the postimplementation period than during the preintervention period (−4.1 vs. −3.6, t = 2.6, p < 0.01). Site 1 had significant improvement between study periods (mean difference = −0.87, t = 2.63, p < 0.01; F = 14.3, p < 0.01). Patients with few ED visits (one to six annual visits, mean difference = −1.55, t = 2.1, p = 0.04) and those with frequent ED visits (7 to 19 annual visits, mean difference = −1.65, t = 3.52, p < 0.01) had a significant decrease in pain scores compared to patients with very frequent ED visits (>19 visits). There was an overall decrease in the use of morphine sulfate (MS) and increase in the use of hydromorphone (χ2 = 105.67, p < 0.001) between study periods and a significant increase in the use of oral (PO) and subcutaneous (SC) routes, with a corresponding decrease in the intravenous (IV) route (χ2 = 13.67, p < 0.001). There were no statistically significant differences in patient‐reported satisfaction with the attempt to manage pain in the ED between study periods (p = 0.54).Conclusions:  While the use of a learning collaborative and implementation of nurse‐initiated analgesic protocols was not associated with improvement in time to administration of the initial analgesic, improvements in the decrease in the arrival to discharge pain score and increased use of hydromorphone and the SC route were noted in adults with SCD in the ED.

1 May 2012 in Journal of Emergency Nursing
Verified
Journal Article
Closed access
PTPaula Tanabe
Paula Tanabe
JPJudith A. Paice
Judith A. Paice
JSJennifer Stancati
Jennifer Stancati
MFMichael Fleming
Michael Fleming

25 February 2021 in Advanced Genetics
Verified
Journal Article
Open access
PDF file
CRCharmaine D. M. Royal
Charmaine D. M. Royal
MBMichael Babyak
Michael Babyak
NSNirmish Shah
Nirmish Shah
SSShantanu Srivatsa
Shantanu Srivatsa
KSKearsley A. Stewart
Kearsley A. Stewart
MMonika Asnani
Monika Asnani
Differences in health outcomes and treatment responses within and between global populations have been well documented. There is growing recognition of the need to move beyond simple inventories and descriptions of these differences and our linear explanations for them, and gain a better understanding of the multifaceted systems and networks underlying them in order to develop more precise and effective remedies. Typical targets for such integrative research have been common multifactorial diseases. We propose sickle cell disease, one of the most common monogenic diseases, as an ideal candidate for elucidating the complexity of the influences of endogenous and exogenous factors on disease pathophysiology, phenotypic diversity, and variations in responses to treatments at both the individual and population levels. We provide data‐informed representations of diverse contributors to sickle cell disease complications that could guide innovative efforts to advance scientific knowledge, clinical practice, and policy formulation related to the disease; help improve outcomes for people worldwide with sickle cell disease; and inform approaches to studying and addressing other diseases.

3 February 2021 in Journal of Pediatric Hematology/Oncology
Verified
Journal Article
Open access
LKLa’kita M.J. Msn Knight
La’kita M.J. Msn Knight
AKAllison A. King
Allison A. King
JSJohn J. Strouse
John J. Strouse
PTPaula PhD Tanabe
Paula PhD Tanabe
Introduction: Sickle cell disease (SCD) is the most common abnormal genetic blood disease that affects ∼100,000 Americans. Approximately 20% to 37% of children with sickle cell anemia have silent cerebral infarcts by the age of 14 years old. Neurocognitive deficits are identified in infants and preschool children with SCD. The purpose of this systematic literature review is to provide a comprehensive understanding of the prevalence, severity, and the associated risk factors for neurodevelopmental delays (NDDs) in children with SCD 5 years of age and younger. Methods: Systematic search of 6 databases identified 2467 potentially relevant publications and 8 were identified through a manual search. Only 24 articles met the inclusion criteria. Results: We identified an increased prevalence of NDDs (cognitive, motor, or both). Children experienced deficits with language, attention and behavior, executive functioning, school readiness and/or academic performance, and motor skills (fine and gross motor functioning). Risk factors include silent cerebral infarcts and strokes, SCD genotype (HbSS>HbSC), other biologic, and social factors. Conclusion: NDDs are common in children ages 0 to 5 years old with SCD. There is an opportunity to improve adherence to national guideline recommendations and early detection practices by pediatricians, hematologists, and other health care providers.